Business Context and Reporting Period
This Form 8-K was filed by Nephros, Inc. on November 5, 2020. The filing primarily reports the appointment of a new Chief Financial Officer and references the issuance of a press release regarding third-quarter 2020 financial results.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained in the referenced press release (Exhibit 99.1), which is furnished but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Material Changes
- Executive Leadership: Daniel D'Agostino was appointed as Chief Financial Officer, effective November 6, 2020.
- Departure: Andrew Astor ceased serving as Chief Financial Officer upon Mr. D'Agostino's appointment.
- Compensation Structure: Mr. D'Agostino's employment agreement includes a base salary of $200,000, eligibility for an annual bonus up to 25%, and a stock option grant.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, or risk factors. It notes that the press release regarding Q3 2020 results is furnished and not incorporated by reference into other filings unless expressly stated. The employment agreement for the new CFO includes termination provisions: three months of salary and benefits if terminated without cause between the first and second anniversary, or six months if terminated after the second anniversary.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for actual Q3 2020 financial performance data, as this 8-K does not list specific numbers.
- Verify the terms of the employment agreement (Exhibit 10.1) regarding the new CFO's vesting schedule and termination benefits.
- Confirm the stock option grant details: 103,973 shares with an exercise price of $6.71 per share.
- Monitor future filings for the formal incorporation of the Q3 2020 results into the company's official record.